For patients with advanced recurrent OC, carboplatin combined with paclitaxel IPCH could significantly reduce the secretion levels of serum tumor markers such as HE4 and DJ-1, enhance the therapeutic effect and reduce the risk of metastasis and the incidence of side effects, with a better clinical application prospect. Here, PARK7 is linked to neoplasm.